Exploring Rapid-Acting Therapies in MDD: Pharmacodynamics and Treatment Evolution

Gus Alva, MD, DFAPA; Carmen Kosicek, MSN, PMHNP-BC; and Roger McIntyre, MD, FRCPC delve into FDA-approved rapid-acting treatments for MDD and TRD, focusing on the sigma-1 agonist and its pharmacodynamics. They explore treatment indications, the rapid onset of action, and how these innovations address unmet clinical needs and shift the treatment paradigm for newly diagnosed depression

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Expert Insights into Navigating MDD Prevalence, Stigma, and Treatment Challenges for Improved Patient Outcomes

EP: 2.Advancing MDD Treatment: From STAR*D Insights to Precision Medicine and Novel Therapeutics

EP: 3.Commentary on Redefining Depression Management with Updated Treatment Strategies

EP: 4.Navigating Non-Response: A Holistic Approach to Patient Care

EP: 5.Transforming MDD: A Patient's Journey with Rapid-Acting Therapy

EP: 6.Quantifying Success: Measuring Depth of Treatment Response in MDD

EP: 7.Access Challenges: Bridging Insurance Gaps for MDD Innovations

EP: 8.Depression Treatment: Expert Guide to Medication Management & Therapeutic Success

EP: 9.From Neuroplasticity to Patient Conversations: Managing Affective Disorders Effectively

EP: 10.Managing Persistent MDD: Case Studies and Treatment Challenges

EP: 11.Evaluating Treatment Failure and Symptomatic Remission in MDD

Now Viewing

EP: 12.Exploring Rapid-Acting Therapies in MDD: Pharmacodynamics and Treatment Evolution

EP: 13.Addressing Unsatisfactory Responses in Chronic MDD

EP: 14.Defining and Managing Treatment-Resistant Depression: Efficacy and Real-World Insights

EP: 15.Optimizing Treatment Response: Insights from Clinical Data and Real-World Experience

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!